Clinical Trial Update: A Study of Erlotinib (Tarceva) in Participants With Resected Head and Neck Squamous Cell Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial of Erlotinib (Tarceva) in patients with resected head and neck squamous cell carcinoma was terminated; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• Tarceva (erlotinib)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Head and Neck Cancer | Phase 3 | Status: TERMINATED | Results posted: 2016-09-26